Skip to content
Starsource Multitrade logo

Starsource Multitrade

506365 BSE
₹114.95

Close ·

P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹114.95 −3.10 −2.63% 1Y
Start ₹118.05

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
0.28%
Debt to Equity
0.00
EPS (TTM)
−₹0.27
Book Value
₹8.60
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
13.37
ROE
0.28%
Dividend Yield
0.00%
EBITDA
−₹1.30 Cr
52W High
₹152.90
52W Low
₹70.01

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

38 Weak

Data confidence 77/100

Category scores

Quality
29
Poor
Returns, margins, earnings quality 24% weight
Valuation
17
Poor
Cheap vs sector & own history 26% weight
Financial Health
55
Average
Solvency, leverage, coverage 10% weight
Momentum
69
Strong
Trend strength, vol-adjusted 13% weight
Ownership
50
Average
FII/DII/promoter flows 26% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

5
  • Stock is trading at 12.3 times its book value
  • Company has low interest coverage ratio.
  • Promoter holding is low: 27.9%
  • Company has a low return on equity of 5.09% over last 3 years.
  • Company has high debtors of 337 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2611
OscillatorsBearish261
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
66.82
Neutral
MACD (12,26,9)
6.92
Bearish
SMA (50)
91.25
Bullish
SMA (200)
101.22
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10YZero base
5YZero base
3YZero base
1YZero base
TTMZero base

Net profit

Net profit growth by window
10YTurned to loss
5YTurned to loss
3YTurned to loss
1YTurned to loss
TTMLoss narrowed by ₹11.67 Cr

Operating cash flow

Operating cash flow growth by window
10YOutflow widened by ₹10.19 Cr
5YOutflow widened by ₹10.21 Cr
3YOutflow widened by ₹9.94 Cr
1YOutflow widened by ₹10.34 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YNo sales
5YNo sales
3YNo sales
1YNo sales
TTMNo sales

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹0.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹0.00 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹0.00 Cr
Mar 2026₹0.53 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹4.68 Cr
Mar 2018₹0.10 Cr
Mar 2019₹0.21 Cr
Mar 2020₹0.42 Cr
Mar 2021₹0.25 Cr
Mar 2022₹0.56 Cr
Mar 2023₹0.05 Cr
Mar 2024₹1.20 Cr
Mar 2025₹0.34 Cr
Mar 2026−₹11.85 Cr

Quarterly Results

₹ Cr
506365 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0
0
0
0
0
0.53
0
0
0.07
Expenses
0.05
0.02
0.02
0.1
0.05
0.02
0.02
0.02
11.83
0.43
0.09
0.07
0.05
Operating Profit
−0.05
−0.02
−0.02
−0.1
−0.05
−0.02
−0.02
−0.02
−11.83
0.1
−0.09
−0.07
0.02
OPM %
—
—
—
—
—
—
—
—
—
18.87%
—
—
28.57%
Other Income
0.43
0.46
0.7
0.25
0.3
0.63
−0.15
−0.16
0.02
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0.38
0.44
0.68
0.15
0.25
0.61
−0.17
−0.18
−11.81
0.1
−0.09
−0.07
0.02
Tax %
0%
0%
0%
293.33%
0%
0%
0%
88.89%
0%
0%
0%
0%
0%
Net Profit
0.38
0.44
0.68
−0.29
0.25
0.61
−0.17
−0.34
−11.81
0.1
−0.09
−0.07
0.02
EPS (₹)
2.53
2.93
4.53
−1.93
1.67
4.07
−1.13
−2.27
−78.73
0.67
−0.6
−0.47
0.13

Profit & Loss

₹ Cr
506365 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
0
0
0
0
0
0
0
0
0
0
0.53
0.6
Expenses
0.12
0.17
0.27
0.34
0.56
0.48
0.34
0.41
0.2
0.19
0.12
0.53
0.64
Operating Profit
−0.12
−0.17
−0.27
−0.34
−0.56
−0.48
−0.34
−0.41
−0.2
−0.19
−0.12
0
−0.04
OPM %
—
—
—
—
—
—
—
—
—
—
—
0%
−6.67%
Other Income
0.5
0.49
5.61
1.11
0.82
1
0.67
0.79
0.3
1.84
0.62
−11.85
0
Interest
0
0
0
0
0
0
0
0
0.01
0
0
0
0
Depreciation
0
0
0
0
0
0.02
0.02
0.02
0.01
0.01
0.01
0
0
PBT
0.38
0.32
5.34
0.77
0.26
0.5
0.31
0.36
0.08
1.64
0.49
−11.85
−0.04
Tax %
26.32%
31.25%
12.17%
85.71%
19.23%
16%
19.35%
−55.56%
37.5%
26.83%
32.65%
0%
—
Net Profit
0.28
0.22
4.68
0.1
0.21
0.42
0.25
0.56
0.05
1.2
0.34
−11.85
−0.04
EPS (₹)
1.87
1.47
31.2
0.67
1.4
2.8
1.67
3.73
0.33
8
2.27
−79
−0.27
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
506365 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
Reserves
3.62
3.84
8.52
8.62
8.83
9.24
9.49
10.05
10.1
11.3
11.64
−0.21
Borrowings
0
0
0.12
0
0
0
0
0
0
0
0
0
Other Liabilities
0.46
0.2
0.58
0.13
0.09
0.22
0.06
0.11
0.02
0.21
0.21
0.53
Total Liabilities
5.58
5.54
10.72
10.25
10.42
10.96
11.05
11.66
11.62
13.01
13.35
1.82
Fixed Assets
0
0
0.01
0
0
0.07
0.05
0.04
0.03
0.02
0.01
0
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
1.68
1.68
0.02
0.02
0.04
0.02
0.04
2.94
3.03
4.4
0.01
0.01
Other Assets
3.9
3.86
10.69
10.23
10.38
10.87
10.96
8.68
8.56
8.59
13.33
1.81
Total Assets
5.58
5.54
10.72
10.25
10.42
10.96
11.05
11.66
11.62
13.01
13.35
1.82

Cash Flow

₹ Cr
506365 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−0.05
−0.43
6.41
−1.66
−5.48
4.83
−0.41
−0.33
−0.68
0.72
−0.28
−10.62
Investing
0.25
0.49
0.52
1.08
0.79
1.01
−0.19
0.97
0.63
−0.52
10.46
0.01
Financing
0
0
−0.5
1.37
0
0
1.96
−2.12
−0.08
−0.15
−0.16
0
Net Cash Flow
0.2
0.06
6.43
0.79
−4.7
5.84
1.36
−1.49
−0.13
0.05
10.02
−10.61
Free Cash Flow
−0.05
−0.43
6.41
−1.66
−5.48
4.83
−0.41
−0.33
−0.68
0.72
−0.28
−10.62
CFO/EBITDA
−25
206
−2,615
294
970
−1,023
94
66
335
−468
67
—

Ratios

506365 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
—
—
—
—
—
—
—
—
—
—
337
Inventory Days
—
—
—
—
—
—
—
—
—
—
—
0
Cash Conversion Cycle
—
—
—
—
—
—
—
—
—
—
—
337
Working Capital Days
—
—
—
—
—
—
—
—
—
—
—
875
ROCE %
7.62%
6.12%
3.62%
7.6%
2.54%
4.75%
2.85%
1.33%
0.78%
13.28%
5.17%
0.28%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Starsource Multitrade insights

55 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 65.86%
  • Promoters 27.89%
  • Others 5.89%
  • DIIs 0.37%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Starsource Multitrade

What does Starsource Multitrade Ltd do?
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company
Where is Starsource Multitrade Ltd (STARSOURCE) listed?
Starsource Multitrade Ltd trades under code 506365 on the BSE.
Which sector does Starsource Multitrade Ltd belong to?
Starsource Multitrade Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Starsource Multitrade Ltd?
Over the last 52 weeks Starsource Multitrade Ltd has traded between ₹70.01 and ₹152.9 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Starsource Multitrade Ltd?
Starsource Multitrade Ltd reported a return on equity of 0.28%. Its debt-to-equity ratio is 0.00.

Company Information

The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company

Website thechemopharmalaboratoriesltd.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/506365.md for Starsource Multitrade Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month